GlassScriptPhysician profile
April Jo Kientz
NPI 1063756765
$4,090.06
in general payments reported to CMS, 2019-2025
22 companies · $1,902 in 2025
The $1,902 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.23 · 2022: $83.95 · 2023: $42.86 · 2024: $2,020 · 2025: $1,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,785 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,784.90 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $770.17 | 2023-2025 | Sotyktu |
| Abbvie INC. | $697.38 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $407.47 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $354.49 | 2023-2025 | Blu-U |
| Janssen Biotech, INC. | $289.60 | 2024-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $272.09 | 2024-2025 | Opzelura |
| Genzyme Corporation | $241.96 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $201.63 | 2024-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $167.87 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $164.09 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $124.50 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $100.41 | 2024-2025 | Adbry, Anzupgo |
| Kerecis Limited | $71.53 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Galderma Laboratories, L.P. | $62.82 | 2024-2025 | Nemluvio |
| Convatec INC. | $49.19 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $20.99 | 2024 | |
| Organon LLC | $18.28 | 2024-2025 | Vtama |
| Reprise Biomedical, INC. | $17.76 | 2025 | Miro3d |
| Verrica Pharmaceuticals INC. | $16.30 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.83 | 2024 | Arazlo |
| Dexcom, INC. | $14.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Kientz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.